HDAC6 and peripheral neuropathy: Recent work has shown that HDAC6 inhibitors, such as Ricolinostat, an inhibitor of histone deacetylase 6, have been effective in improving DPN (252), chemotherapy-induced peripheral neuropathy (CIPN) (253, 254),and peroneal muscular dystrophy (CMT) type 2 disease (255) in animal models with good safety and tolerability.